TY - JOUR
T1 - Prevalence of depression and anxiety in women newly diagnosed with vulvovaginal atrophy and dyspareunia
AU - Moyneur, Erick
AU - Dea, Katherine
AU - Derogatis, Leonard R.
AU - Vekeman, Francis
AU - Dury, Alain Y.
AU - Labrie, Fernand
N1 - Funding Information:
Received February 7, 2019; revised and accepted June 24, 2019. From the 1Statlog Econometrics Inc., Montreal, QC, Canada; 2Johns Hopkins School of Medicine, Baltimore, MD; and 3Endoceutics Inc., Québec, QC, Canada. *Author Fernand Labrie is deceased. Funding/support: This study was funded by Endoceutics Inc. Financial disclosure/conflicts of interest: Fernand Labrie is the founder and Chief Executive Officer of Endoceutics Inc. Alain Y. Dury is an employee of Endoceutics Inc. Erick Moyneur, Katherine Dea, and Francis Vekeman are employees of StatLog Econometrics, Inc., which has received consultancy fees from Endoceutics Inc. Leonard R. Der-ogatis is an employee of Johns Hopkins School of Medicine and consultant of Endoceutics Inc. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Website (www.menopause.org). Address correspondence to: Erick Moyneur, MA, 3 Place Ville Marie Suite 400, Montreal, Québec H3B 2E3, Canada. E-mail: emoyneur@statlogeconometrics.com
Publisher Copyright:
© 2020 by The North American Menopause Society.
PY - 2020
Y1 - 2020
N2 - Objective:To quantify the association between vulvovaginal atrophy and depression, major depressive disorder, and anxiety.Methods:Women with vulvovaginal atrophy from the Truven Health MarketScan Commercial and Medicare Supplemental Databases (01/2010-09/2016) with ≥365 days of continuous insurance coverage before and after the first vulvovaginal atrophy/dyspareunia diagnosis (index date) were selected. Women with vulvovaginal atrophy were matched 1:3 to women without (controls) according to age, calendar year, health plan, and region. The study period spanned from 12 months before to 12 months after index date. The ratios of diagnosed depression, major depressive disorder, and anxiety among women with vulvovaginal atrophy and the controls were calculated. Logistic regressions adjusting for proxies of menopause were used to compare prevalence.Results:In all, 125,889 women with vulvovaginal atrophy and 376,057 controls were included (mean age 60.7 [45-101]). The prevalence of depression, major depressive disorder, and anxiety was higher among women with vulvovaginal atrophy compared with controls (23.9% vs 18.9%, 6.3% vs 4.7%, 16.6% vs 11.3%), with prevalence ratios of 1.26, 1.33, and 1.47, respectively (all P<0.0001). Highest prevalences and differences were observed in younger women. Findings were consistent when analyzing newly diagnosed conditions. When adjusting for proxies of menopause (insomnia, vasomotor symptoms, dysuria, and estrogen therapy), vulvovaginal atrophy remained significant (prevalence odds ratios; depression 1.23, major depressive disorder 1.22, anxiety 1.39; all P<0.0001).Conclusions:Vulvovaginal atrophy is associated with a significantly higher prevalence/incidence of depression, major depressive disorder, and anxiety. The higher prevalence/incidence and greater differences in younger women highlight the need for a multidisciplinary approach and early diagnosis/management of vulvovaginal atrophy.
AB - Objective:To quantify the association between vulvovaginal atrophy and depression, major depressive disorder, and anxiety.Methods:Women with vulvovaginal atrophy from the Truven Health MarketScan Commercial and Medicare Supplemental Databases (01/2010-09/2016) with ≥365 days of continuous insurance coverage before and after the first vulvovaginal atrophy/dyspareunia diagnosis (index date) were selected. Women with vulvovaginal atrophy were matched 1:3 to women without (controls) according to age, calendar year, health plan, and region. The study period spanned from 12 months before to 12 months after index date. The ratios of diagnosed depression, major depressive disorder, and anxiety among women with vulvovaginal atrophy and the controls were calculated. Logistic regressions adjusting for proxies of menopause were used to compare prevalence.Results:In all, 125,889 women with vulvovaginal atrophy and 376,057 controls were included (mean age 60.7 [45-101]). The prevalence of depression, major depressive disorder, and anxiety was higher among women with vulvovaginal atrophy compared with controls (23.9% vs 18.9%, 6.3% vs 4.7%, 16.6% vs 11.3%), with prevalence ratios of 1.26, 1.33, and 1.47, respectively (all P<0.0001). Highest prevalences and differences were observed in younger women. Findings were consistent when analyzing newly diagnosed conditions. When adjusting for proxies of menopause (insomnia, vasomotor symptoms, dysuria, and estrogen therapy), vulvovaginal atrophy remained significant (prevalence odds ratios; depression 1.23, major depressive disorder 1.22, anxiety 1.39; all P<0.0001).Conclusions:Vulvovaginal atrophy is associated with a significantly higher prevalence/incidence of depression, major depressive disorder, and anxiety. The higher prevalence/incidence and greater differences in younger women highlight the need for a multidisciplinary approach and early diagnosis/management of vulvovaginal atrophy.
KW - Anxiety
KW - Depression
KW - Prevalence
KW - Risk
KW - Vulvovaginal atrophy
UR - http://www.scopus.com/inward/record.url?scp=85078694167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078694167&partnerID=8YFLogxK
U2 - 10.1097/GME.0000000000001450
DO - 10.1097/GME.0000000000001450
M3 - Article
C2 - 31688416
AN - SCOPUS:85078694167
SN - 1072-3714
VL - 27
SP - 134
EP - 142
JO - Menopause
JF - Menopause
IS - 2
ER -